Roche announced that it has launched Elecsys ProGRP test globally (except US) for more precise diagnosis in lung cancer by expanding cancer diagnostics portfolio.
Elecsys ProGRP is a test that distinguishes between the two main types of lung cancer – small cell (SCLC) and non-small cell (NSCLC) lung cancer – and can help diagnose early-stage SCLC.
The ProGRP test allows a combined application with NSE from a single sample tube and can be determined in serum or plasma.
The Elecsys ProGRP test, for use on Roche’s cobas modular analysers, can be used with serum or plasma. ProGRP and NSE can therefore be determined in serum from a single sample tube. As NSE cannot be measured in plasma, this unique feature improves workflow and efficiency in the laboratory if measurement of both ProGRP and NSE is necessary.
Lung cancer is one of the most common cancers worldwide. Approximately 1.35 million new cases are diagnosed every year, representing almost 13% of all new cancer diagnoses.